#	Pagina
attuale pagina	/open-h2020/projects/197190/index.html

Opendata, web and dolomites

proLungPlasma

Validation of a Lung Cancer Plasma Reflex Test Using Epigenetic Biomarker for Cancer Detection

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

proLungPlasma project word cloud

Explore the words cloud of the proLungPlasma project. It provides you a very rough idea of what is the project "proLungPlasma" about.

unacceptably mdx successfully epigenomics cancer positive assay forms ing epi false dna outstanding aberrant occurring business computer dose proprietary diseases validation lung performed plays mshox2 unfortunately leader methylation standardized deadly differentiation screening successful upcoming engaged detecting burdened clinical prolungplasma reducing off markets diagnosis regulation reflex prolung detects global validate newly 1998 tests epigenetic innovation anticipated kick regulatory blueprint discovery urgently ldct colorectal platform market rates ivd cell biological biomarker expertise materials frequently requisite blood tool plasma fundamental tomography kits

Project "proLungPlasma" data sheet

The following table provides information about the project.

Coordinator	EPIGENOMICS AG Organization address address: KLEINE PRAESIDENTENSTR 1 city: BERLIN postcode: 10178 website: www.epigenomics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.epigenomics.com/products/epi-prolung/
Total cost	2˙772˙527 €
EC max contribution	2˙772˙527 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2017-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	EPIGENOMICS AG EPIGENOMICS AG Organization address address: KLEINE PRAESIDENTENSTR 1 city: BERLIN postcode: 10178 website: www.epigenomics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	coordinator	2˙772˙527.00

Map

Project objective

The objective of “proLungPlasma” is the clinical validation of a lung cancer test, which detects DNA methylation of the specific biomarker mSHOX2. Methylation of DNA is an important epigenetic process involved in fundamental biological processes as development and cell differentiation. Aberrant DNA methylation plays a major role in cancer development. Epigenomics is very successfully engaged in epigenetic research since 1998 resulting in an outstanding proprietary platform for epigenetic biomarker discovery for cancer. Epigenomics is now market leader in epigenetic biomarker test kits detecting most frequently occurring forms of cancer as colorectal and lung cancer from different sample materials. Lung Cancer is the most deadly of all cancer diseases. Unfortunately, lung cancer screening by Low Dose Computer Tomography (LDCT) is burdened by unacceptably high false positive rates. The newly developed Epi proLung Plasma Reflex Assay is urgently required as a tool for reducing false positive rates. Therefore, the Epi proLung Plasma Reflex Assay is a highly anticipated pre-requisite for successful implementation of lung cancer screening in Europe. This business innovation project will validate the Epi proLung Plasma Reflex Assay for the diagnosis of lung cancer in plasma under the upcoming new IVD regulation. The validation process to be performed in this business innovation project will be used as a blueprint for the standardized validation of all further epigenetic biomarker blood tests. Epigenomics’ established test platform, its product development and regulatory expertise, and the standardized validation process are expected to kick-off further strong growth on major global MDx markets.

Deliverables

List of deliverables.
Registration Documents	Documents, reports	2019-05-30 12:55:42

Take a look to the deliverables list in detail: detailed list of proLungPlasma deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2017	Gunter Weiss, Anne Schlegel, Denise Kottwitz, Thomas KÃ¶nig, Reimo Tetzner Validation of the SHOX2 / PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease published pages: 77-84, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2016.08.123	Journal of Thoracic Oncology 12/1	2019-07-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROLUNGPLASMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROLUNGPLASMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development